Skip To Main Content
Seungryel Han on Muck Rack

Seungryel Han

As seen in: Outsourced Pharma, Cell & Gene
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Seungryel

Contact Seungryel, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

A New Paradigm In T-Cell Lymphoma Treatment: CD5 CAR-NK

|
By Seungryel Han, Miyoung Jung, GC Cell, Louis Garguilo Verified
| Outsourced Pharma
By Seungryel Han and Miyoung Jung, GC Cell T-cell lymphomas (TCLs) are a rare and aggressive subset of non-Hodgkin lymphomas, accounting for 10–15% of cases. Their incidence is rising, particularly among older adults, intensifying the urgent need for more effective treatment strategies. Standard therapies, such as CHOP-based chemotherapy and hematopoietic stem cell transplantation (HSCT), are often inadequate, resulting in poor response rates, high toxicity, and frequent relapses.
Open in Who Shared Issue with article?

A New Paradigm In T-Cell Lymphoma Treatment: CD5 CAR-NK

|
By Miyoung Jung, GC Cell, Seungryel Han
| Cell & Gene Verified
By Seungryel Han and Miyoung Jung, GC Cell T-cell lymphomas (TCLs) are a rare and aggressive subset of non-Hodgkin lymphomas, accounting for 10–15% of cases. Their incidence is rising, particularly among older adults, intensifying the urgent need for more effective treatment strategies. Standard therapies, such as CHOP-based chemotherapy and hematopoietic stem cell transplantation (HSCT), are often inadequate, resulting in poor response rates, high toxicity, and frequent relapses.
Open in Who Shared Issue with article?
See all 2 articles